Table 3.
Adverse events of brolucizumab.
| Characteristics | Total (N = 81) | Good-response group (N = 67) | Poor-response group (N = 14) | p-value |
|---|---|---|---|---|
| Switch back, n (%) | 12 (14.8%) | 7 (10.4%) | 5 (35.7%) | 0.029ǂ |
| Cause | ||||
| Adverse events, n (%) | 5 (7.46%) | 2 (14.3%) | ||
| Low response, n (%) | – | 3 (21.4%) | ||
| Other, n (%) | 2 (2.99%) | – | ||
| Adverse events, n (%) | 8 (9.88%) | 6 (8.96%) | 2 (14.3%) | 0.621ǂ |
| Anterior uveitis, n (%) | 2 (2.47%) | 1 (1.49%) | 1 (7.14%) | |
| Vitreous opacity, n (%) | 5 (6.17%) | 4 (5.97%) | 1 (7.14%) | |
| Retinal vascular occlusion, n (%) | 1 (1.23%) | 1 (1.49%) | - | |
p-values for the difference between the good and poor responder groups were obtained. ǂFisher’s exact test. Significant values are in bold.